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to Medications for Opioid Use Disorder 
Alice Fiddian-Green, MPH; Aline Gubrium, PhD; Calla Harrington, MSW, MPH; Elizabeth Evans, PhD
Department of Health Promotion and Policy, School of Public Health & Health Sciences, UMass Amherst
Ø Opioid use disorder (OUD) is a chronic 
health condition best managed with long-
term treatment with medications (MOUD)
§ Methadone, buprenorphine, naltrexone
Ø Less than 20% of people with OUD 
receive treatment
Ø Women with OUD do not remain engaged 
with MOUD long enough to achieve 
sustained benefits  
Ø Aim: Identify barriers and facilitators 
that impact women’s MOUD adherence 
Fear & anxiety of MOUD-related stigma
Ø Social networks & social media messaging 
that MOUD is “substituting one drug for 
another”
Gender-specific side effects
Ø Weight gain
Ø Tooth decay
Ø Interactions with mental health medications
Consequences of being discovered as a 
MOUD client
Ø Loss of child custody
Ø Children being bullied
Ø Loss of employment & workplace stigma
Ø Associations with sex-work
Research design, site, and recruitment
Ø Community-Partnered Research Approach
Ø Springfield & Holyoke, MA
§ Community-based outpatient programs
Ø Word of mouth, clinician referrals, flyers
Data collection and analysis
Ø Semi-structured interviews & focus groups
§ August- December 2018
§ 1 ½- 2 hours
§ Recorded & professionally transcribed
§ $25 gift card
Ø Grounded theory analysis 
Strengths and limitations
Ø Qualitative, exploratory data (+)
Ø Non-random convenience sample (-)
Program characteristics
Ø Sense of “safety” for women with trauma histories
Ø Peer-mentor model
§ Relatability
§ Hope and motivation
Gender-specific skill building
Ø Replacement behaviors that build self-esteem
Ø Boundary setting with active users
§ Friends, partners, family
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To improve gender-specific treatment:
Ø Integrate recovery coaches/peer mentors
Ø Provide education about MOUD side-effects
Ø Provide relevant skill-building activities
Ø Outreach efforts to address community-level 
gender-specific stigmas
To understand medication preference
Ø Further examine methadone preference
Ø Identify negative buprenorphine side effects
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Ø 20 women enrolled in outpatient MOUD 
treatment program for >90 days
 
 Women (N=20) 
Age (mean + SD)  36.6 + 9.5 years 
 
Race/ethnicity 
White, Non-Hispanic  
Black, Non-Hispanic  
Hispanic or Latina/x 
 
   65% 
     5% 
   30% 
 
Educational attainment 
< High school/GED 
High school/GED 
Trade/vocational/tech training post-high school 
Some college/Associate’s degree 
Bachelor’s degree 
 
     5% 
   25% 
     5% 
   60% 
     5% 
 
Employment status 
Employed full-time 
Employed part-time 
Laid off/ Unemployed  
Disabled and not working 
Retired and not working 
 
   20% 
   15% 
   30% 
   25% 
   10% 
 
Adult household income in last 12 months 
<$10,000   
$10,001-$20,000   
$20,001-$40,000  
$40,001-$75,000   
 
   45% 
   35% 
   15% 
     5% 
 
Opioid use (mean + SD) 
Age at 1st initiation, all opioids 
Average duration of use, all opioids 
 
   26.6 + 7.1 years 
     4.6 + 5.0 years  
 
Methadone treatment  
Enrolled in methadone program 
Age at 1st first treatment (mean + SD) 
Methadone treatment duration (mean + SD) 
 
  100% 
   31.3 + 11.1 years 
     2.8 + 2.4 years 
 
Buprenorphine treatment 
Prefers methadone over buprenorphine  
Knows about buprenorphine 
Experienced negative buprenorphine side effects 
Did not seek buprenorphine 
Heard of negative buprenorphine side effects 
 
    70% 
    70% 
    45% 
    40% 
    30% 
 
 
 
 
